<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03613428</url>
  </required_header>
  <id_info>
    <org_study_id>HX-ETP-01</org_study_id>
    <nct_id>NCT03613428</nct_id>
  </id_info>
  <brief_title>Ruxolitinib Plus LVP in Patients With R/R ETP-ALL</brief_title>
  <official_title>Phase I/II Study of Ruxolitinib Plus L-asparaginase, Vincristine, and Prednisone in Adult Patients With Relapsed or Refractory Early T Precursor Acute Lymphocytic Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sichuan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sichuan University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine the maximum tolerated dose (MTD), if present, and dose schedule of ruxolitinib
      in combination with L-ASP, vincristine, and prednisone (LVP) in patients with
      relapsed-and-refractory (R/R) early T precursor acute lymphocytic leukemia (ETP-ALL). Once
      determined, the purpose of this study will be to determine the efficacy of ruxolitinib in
      combination with LVP in patients with R/R ETP-ALL.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 1, 2018</start_date>
  <completion_date type="Anticipated">March 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Open label dosing cohorts will evaluate oral ruxolinitib (doses ranging from 10 - 80 mg) in combination with vincristine (1.4 mg/m2) and oral prednisone (1 mg/kg, 5 days a week for 4 weeks).</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Establish optimal dose of ruxolitinib</measure>
    <time_frame>Upon completion of a 28 day treatment cycle</time_frame>
    <description>Determine maximum tolerated dose (MTD) of ruxolitinib</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate safety by assessing toxicities</measure>
    <time_frame>Upon completion of a 28 day treatment cycle</time_frame>
    <description>Evaluate safety by assessing possible toxicities of thrombocytopenia, neutropenia, serum creatinine, total bilirubin, diarrhea, and/or vomiting.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall response</measure>
    <time_frame>At the end of Cycle 2 (each cycle is 60 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete response</measure>
    <time_frame>At the end of Cycle 2 (each cycle is 60 days)</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Acute T Cell Leukemia</condition>
  <arm_group>
    <arm_group_label>ruxolitinib, vincristine, prednisone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Open label dosing cohorts will evaluate oral ruxolitinib (doses ranging from 10 - 80 mg) in combination with vincristine (1.4 mg/m2) and oral prednisone (1 mg/kg, 5 days a week for 4 weeks).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ruxolitinib</intervention_name>
    <description>Dose escalation up to 80 mg administered orally</description>
    <arm_group_label>ruxolitinib, vincristine, prednisone</arm_group_label>
    <other_name>JAK1/JAK2 inhibitor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vincristine</intervention_name>
    <description>1.4 mg/m2 i.v. weekly for 4 weeks</description>
    <arm_group_label>ruxolitinib, vincristine, prednisone</arm_group_label>
    <other_name>Oncovin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
    <description>1 mg/kg orally 5 consecutive days per week for 4 weeks.</description>
    <arm_group_label>ruxolitinib, vincristine, prednisone</arm_group_label>
    <other_name>steroid</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subjects with early T-precursor ALL, with any of the following:

               -  refractory to primary induction therapy or refractory to salvage therapy,

               -  in untreated first relapse with first remission duration &lt;12 months

               -  in untreated second or greater relapse

               -  relapse at any time after allogeneic HSCT

          2. Subject has received intensive combination chemotherapy for the treatment of ALL for
             initial treatment or subsequent salvage therapy.

          3. Greater than 5% blasts in the bone marrow

          4. Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2

        Exclusion Criteria:

          1. Malignancy other than ALL within 5 years before recruitment, except for adequately
             treated selected cancers without evidence of disease

          2. Current relevant central nervous system (CNS) pathology or known or suspected CNS
             involvement

          3. Isolated extramedullary disease

          4. Current autoimmune disease or history of autoimmune disease with potential CNS
             involvement

          5. Autologous HSCT within 6 weeks or allogeneic HSCT within 12 weeks before blinatumomab
             treatment, or eligibility for allogeneic HSCT at the time of enrollment

          6. Active acute grade 2 to 4 graft versus host disease (GvHD) according to Glucksberg et
             al (1974) criteria that required systemic treatment to prevent or treat GvHD 2 weeks
             before blinatumomab treatment

          7. Known exclusion criteria to investigator choice of SOC chemotherapy (per package
             insert)

          8. Cancer chemotherapy or radiotherapy with 2 weeks, or immunotherapy (included CD19
             therapy) within 4 weeks of protocol-specified therapy

          9. Abnormal laboratory values (alanine or aspartate transaminase [ALT or AST] or alkaline
             phosphatase [ALP] ≥ 5 × upper limit of normal [ULN]; total bilirubin or creatinine ≥
             1.5 × ULN), or calculated creatinine clearance &lt; 60 mL/min.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>13 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jie Ji, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>West Chinia Hospital, Sichuan University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jie Ji, MD</last_name>
    <phone>86-18980605802</phone>
    <email>jieji@scu.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ting Liu, MD</last_name>
    <phone>86-28-85422370</phone>
    <email>liuting@scu.edu.cn</email>
  </overall_contact_backup>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>July 16, 2018</study_first_submitted>
  <study_first_submitted_qc>August 1, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 3, 2018</study_first_posted>
  <last_update_submitted>August 1, 2018</last_update_submitted>
  <last_update_submitted_qc>August 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 3, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sichuan University</investigator_affiliation>
    <investigator_full_name>Jie Ji</investigator_full_name>
    <investigator_title>Clinical Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, T-Cell</mesh_term>
    <mesh_term>Precursor T-Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Vincristine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

